• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

Vaccine Effectiveness Against Hospitalization in the U.S. for Moderna, Pfizer and J&J

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Self et al. (CDC MMWR, 2021) assessed vaccine effectiveness (VE) of the three available vaccines in preventing COVID-19 hospitalization, and compared serum antibody levels after full vaccination with the Moderna, Pfizer-BioNTech, or Janssen COVID-19 vaccine

METHODS:

  • Case-control analysis (during March 11 to August 15, 2021)
  • Population
    • ≥18 years
    • Without an immunocompromising condition
    • Hospitalized at 21 U.S. hospitals across 18 states
  • Exposures
    • Case-patients: Admitted to a hospital with COVID-19–like illness and a positive SARS-CoV-2 RT-PCR or antigen test result
    • Control-patients: Admitted to a hospital with negative SARS-CoV-2 RT-PCR test result
  • Study design
    • In addition to VE case-control analysis, additional postvaccine antibody analysis was conducted against three SARS-CoV-2 antigens (spike protein, the spike receptor binding domain [RBD], and nucleocapsid)
    • IgG levels reported in international binding antibody units (BAU)
  • Primary outcome
    • VE against COVID-19 hospitalization

RESULTS:

  • 1682 COVID-19 patients | 2007 control patients
    • Fully vaccinated with Moderna: 12.9%
    • Fully vaccinated with Pfizer: 20.0%
    • Fully vaccinated with Janssen: 3.1%
    • Nonvaccinated: 64.0%
  • VE against COVID-19 hospitalization was higher for the Moderna vaccine than for the Pfizer vaccine (P=0.011)
    • Moderna VE: 93%
    • Pfizer VE: 88%
  • VE for both mRNA vaccines were higher than for the Janssen vaccine (all P<0.001)
    • Janssen VE: 71%
  • VE remained consistent over time for Moderna, but declined significantly for Pfizer
    • Moderna (P=1.000)
      • 14 to 120 days (median 66 days) after second dose: 93%
      • >120 days (median 141 days): 92%
    • Pfizer (P<0.001)
      • 14 to 120 days (median 69 days) after second dose: 91%
      • 120 days (median 143 days): 77%
  • 100 healthy volunteers for antibody testing
    • Moderna: 32 participants
    • Pfizer: 51 participants
    • Janssen: 17 participants
  • Anti-RBD levels were higher in participants vaccinated with the Moderna vaccine compared with the other two vaccines
    • Moderna
      • Median (IQR) 4333 (3134 to 7197) BAU/mL
    • Pfizer (P=0.033)
      • Median (IQR) 3217 (2048 to 4668) BAU/mL
    • Janssen (P<0.001)
      • Median (IQR) 57 (26 to 94) BAU/mL
  • Anti-spike IgG levels in participants vaccinated with the Moderna vaccine were not significantly different from those in Pfizer recipients, but were significantly higher than those who received Janssen
    • Moderna
      • Median (IQR) 3236 (2125 to 4975) BAU/mL
    • Pfizer (P=0.217)
      • Median (IQR) 2983 (1954 to 4059) BAU/mL
    • Janssen (P<0.001)
      • Median (IQR) 59 (30 to 104) BAU/mL

CONCLUSION:

  • Moderna and Pfizer vaccines had a VE against COVID-19 hospital admission of 93% and 88% respectively
    • Janssen’s VE was somewhat lower, at 71%
  • Antibody levels were similarly elevated in those that received an mRNA vaccine, while Janssen vaccine recipients had significantly lower titers
  • Pfizer vaccine protection declined 4 months after vaccination
  • The Moderna vaccine produced higher postvaccination anti-RBD antibody levels than Pfizer, which may be due to higher mRNA content in Moderna, or the timing between doses

Learn More – Primary Sources:

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

COVID-19 mRNA Vaccine Effectiveness in the Real World Including in Those Partially Immunized
COVID-19 Vaccine Effectiveness: Cases and Hospitalizations in New York by Vaccination Status
How Effective are Pfizer and AstraZeneca Vaccines vs the Delta Variant?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site